Litteraturhenvisninger ifm. vaccination med PPV23 og PCV13 

Bonten M.J., Huijts S.M., Bolkenbaas M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015. 372(12): p1114-25.

Centers for Disease Control and Prevention, Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 1997. 46(RR-8): p. 1-24.

Centers for Disease Control and Prevention, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep, 2012. 61(40): p. 816-9.

Centers for Disease Control and Prevention and Advisory Committee on Immunization Practices, Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep, 2010. 59(34): p. 1102-6.

Cordonniner C et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases 2019 19(6): P e200-212.

Djennad A., Ramsay M.E., Pebody R., et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine 2018. 6: p 42-50.

Folkehelseinstituttet, Anbefalinger for bruk av pneumokokkvaksine utenfor barnevaksinasjonsprogram i Norge. 2013.

Ganaie, F. et al. A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus, Mbio, 2020. 11(3). 

King, M.D., et al., Recurrent invasive pneumococcal disease: a population-based assessment. ClinInfect Dis, 2003. 37(8): p. 1029-36. 

Konradsen, H.B., Humoral immune response to pneumococcal vaccination. Prevention of infections with Streptococcus pneumoniae by immunization. APMIS Suppl, 1996. 60: p. 1-28.

Ljungman, P., et al., Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant, 2009. 44(8): p. 521-6.

Mufson, M.A., H.E. Krause, and G. Schiffman, Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med, 1983. 173(2): p. 270-5.

Mufson, M.A., et al., Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci, 1987. 293(5): p. 279-84.

Robert Koch Institut, Wissenschaftliche Begründung für die Aktualisierung der PneumokokkenImpfempfehlung für Senioren. Epidemiologisches Bulletin, 2016. 36.

Statens Serum Institut, Konjugeret pneumokokvaccine godkendt til brug hos voksne over 50 år. EPINYT, 2012. 2. Statens Serum Institut, Vaccinationsprogram mod pneumokoksygdom til personer der er fyldt 65 år og til risikogrupper. EPI-NYT, 2020. 16.

Shatz, D.V., et al., Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma, 1998. 44(5): p. 760-5; discussion 765-6. 

Tomblyn, M., et al., Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant, 2009. 15(10): p. 1143-238.

Winje BA, et al. Efficacy and effectiveness of pneumococcal vaccination in adults – an update of the literature. [Effekt av pneumokokkvaksine hos eldre] Report 2019. Oslo: Norwegian Institute of Public Health, 2019